Table 1.
The data of patients studied
| Number | Gender | Age | HLA-A2 | ELISA | DIMERX (%)a |
DIMERX (%)b |
||
|---|---|---|---|---|---|---|---|---|
| H1121 | S1203 | H1121 | S1203 | |||||
| 1 | Female | 21 | + | + | 0 | 13 | 0.01 | 0.19 |
| 2 | Female | 23 | + | + | 0 | 12 | 0.00 | 0.25 |
| 3 | Female | 21 | + | + | 1 | 35 | 0.02 | 0.42 |
| 4 | Female | 23 | + | + | 0 | 25 | 0.01 | 0.33 |
| 5 | Female | 21 | + | + | 3 | 15 | 0.00 | 0.28 |
| 6 | Female | 21 | − | + | 0 | 0 | 0.02 | 0.00 |
| 7 | Female | 20 | − | + | 0 | 0 | 0.00 | 0.00 |
| 8c | Female | 22 | + | − | 2 | 1 | 0.00 | 0.02 |
| 9c |
Female |
23 |
+ |
− |
0 | 0 | 0.00 | 0.00 |
a
The number of colored spots per 105 cells in wells with ELISPOT assay.
b
The percentages of CD8+DimerX+ cells in CD8+ populations.
c
Two female and age-matched HLA-A2+ health donors who were not infected with SARS-CoV when the samples were collected.